Science & Enterprise subscription

Follow us on Twitter

  • Covid-19 is truly a global pandemic, and today we offer a new map showing where the disease has spread.…
    about 18 hours ago
  • New post on Science and Enterprise: Infographic – Covid-19 Global Spread Near Complete #Science #Business
    about 18 hours ago
  • University engineering and medical groups designed simple, open-source face shields for health care workers on the…
    about 2 days ago
  • New post on Science and Enterprise: Univ. Labs Design, Produce Medical Face Shields #Science #Business
    about 2 days ago
  • An analysis of health care spending by large employers shows both companies and their employees are saving money fr…
    about 2 days ago

Please share Science & Enterprise

Genetic Blood Transfusion Diagnostic Approved by FDA

Blood bag (NIH)

(National Institutes of Health)

23 May 2014. The U.S. Food and Drug Administration approved a molecular diagnostic test to help determine genetic compatibility for blood transfusions, a particular need for people requiring frequent transfusions. The PreciseType HEA Molecular BeadChip Test is made by BioArray Solutions, a subsidiary of Immucor, a developer of diagnostics for transplants and transfusions in Norcross, Georgia.

The BioArray Solutions test determines the genetic composition for major ABO blood types, and 36 antigens expressed on the surface of red blood cells found across 11 blood groups. This more comprehensive genetic matching helps prevent alloimmunization, a condition where the recipient’s immune system develops antibodies that attack the transfused blood cells. Alloimmunization is a particular concern for people needing frequent transfusions, including those with hereditary blood diseases such as thalassemia and sickle-cell anemia.

The American Red Cross says more than 41,000 blood transfusions are needed in the U.S. every day, with the average red blood cell transfusion equaling 3 pints. Sickle-cell disease affects some 70,000 people in the U.S., including 1,000 babies born each year with the condition. In addition, people diagnosed with cancer require frequent blood transfusions, sometimes daily, during their chemotherapy treatments.

Current methods for analyzing blood genetics require testing the blood with reagents specific to each antigen, which can be a lengthy process and require having all of the necessary reagents on hand. The PreciseType HEA, on the other hand, tests for all 36 antigens simultaneously, providing faster turnaround. The diagnostic also makes it possible for blood banks to identify donations with rare or unusual antigens that can be saved for special cases.

The PreciseType HEA test received a CE mark indicating approval for use in Europe in 2010. Since then, the American Red Cross has used the test for research purposes at one of its facilities.

Read more:

*     *     *

Please share Science & Enterprise ...

1 comment to Genetic Blood Transfusion Diagnostic Approved by FDA